Basecamp Research Raises $140m To Advance AI-Designed Cell And Gene Therapies
Basecamp Research has secured $140 million in Series C funding as it looks to move a new generation of AI-designed therapeutics towards clinical development, beginning with in vivo cell therapy.
The London and Boston-based biotechnology company is developing medicines using artificial intelligence models trained on large-scale biological datasets, with the aim of designing therapies capable of reprogramming cells inside the human body.
The oversubscribed funding round was led by S32, with participation from NVIDIA, Anthropic’s Anthology Fund, Catalio Capital Management, European Tech Collective, Firebrand River Capital, Inception Fund, King Philanthropies, NATO Innovation Fund, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI and True Ventures.
The investment will be used to train a new generation of Basecamp Research’s EDEN biological foundation models, progress its therapeutic pipeline and expand partnerships with pharmaceutical companies.
Targeting In Vivo Cell Therapy
One of the first areas being targeted by Basecamp is in vivo cell therapy, an approach that seeks to reprogramme a patient’s cells directly inside the body.
Existing cell therapies can involve complex manufacturing processes in which cells are removed from a patient, modified outside the body and subsequently returned. Such treatments can also carry substantial manufacturing costs.
Basecamp says its technology could ultimately enable more complex genetic instructions to be delivered directly to cells.
The company is combining EDEN’s ability to design long and complex DNA sequences with large serine recombinases, which can integrate DNA sequences into the genome.
It believes the approach could potentially lead to cell therapies that are more sophisticated and customisable while being simpler to administer. Possible future applications include treatments for cancer and autoimmune diseases.
Basecamp said it has already demonstrated encouraging preclinical results across a number of therapeutic modalities and disease areas. However, the programmes remain at the preclinical stage and will need to progress through further development and clinical testing before their potential benefits for patients can be established.
Glen Gowers, co-founder and CEO of Basecamp Research, said: “We believe the future of medicine lies in reprogramming the body to repair itself. We design the models and the medicines to teach it how.
“AI-based approaches promise to change what’s possible for patients who currently have few alternatives. This funding brings this technology closer to those who need it most.”
Using AI To Design New Medicines
At the heart of the company’s technology is EDEN, a biological foundation model trained using Basecamp’s Trillion Gene Atlas.
The company describes the Atlas as the world’s largest proprietary biological AI training dataset. It has been developed with partners including NVIDIA, Anthropic, PacBio and Ultima Genomics and incorporates biological data gathered through access and benefit-sharing partnerships in more than 30 countries across all seven continents.
Rather than being developed to perform a single scientific task, EDEN is intended to identify patterns across a broad range of biological information and build a more general understanding of the way DNA functions.
Basecamp says this allows its models to generate potential therapeutic candidates using information about a disease. Applications being explored include the design of cell and gene therapies, enzymes and peptides.
The company has previously demonstrated aspects of the approach through its work with Anthropic on Claude Science.
André Hoffmann, Vice-Chairman of Roche and one of the senior industry figures investing in the funding round, said: “The biotechnology revolution that began fifty years ago transformed how we make medicines. Personalised, AI-designed therapeutics represent the next transformation of that journey.
“Basecamp Research has built the full platform to deliver it, from biological data to trained models to designed therapies. This will be key in helping the industry to continue to innovate.”
Pharmaceutical Partnerships Set To Expand
Alongside developing its own therapeutic pipeline, Basecamp Research plans to increase its work with pharmaceutical companies.
The business has appointed Richard Pearce, formerly of Biogen, as Chief Business Officer to support the expansion of those partnerships.
Andy Conrad, General Partner at S32 and former CEO of Google’s Verily, will also join Basecamp Research’s Board of Directors following the Series C investment.
He said: “AI is opening up new possibilities across every part of society, but perhaps nowhere is the potential more meaningful than in human health.
“The ability to combine AI, biological data and scientific insight could transform how we understand disease, discover medicines and ultimately improve and extend people’s lives. Basecamp Research is building an important technology platform at the center of that opportunity.”
The latest investment reflects growing interest in using generative and foundation-model AI technologies not simply to analyse biomedical data, but to design new biological molecules and therapeutic interventions.
For Basecamp Research, the next significant test will be translating results from its AI-designed preclinical programmes into therapies capable of demonstrating safety and efficacy in human clinical trials.
The company is headquartered in London and also operates offices and laboratories in Cambridge, Massachusetts.